Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trialResearch in context

Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trialResearch in context

Summary: Background: The PHILA study suggests that pyrotinib, trastuzumab, and docetaxel significantly improved progression-free survival (PFS) compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2-positive metastatic breast cancer. In this study, we aimed to investigate...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuning Liu, Bo Lan, Yuanyi Wang, Tao Yang, Lixi Li, Hewei Ge, Cheng Zeng, Binghe Xu, Haili Qian, Fei Ma
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:EBioMedicine
Subjects:
PHILA study
Pyrotinib
Trastuzumab
HER2-positive breast cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424004158
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items